EE210 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy as Neoadjuvant Therapy and Continued as a Single Agent as Adjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer in Greece
Abstract
Authors
N. Yfantopoulos C. Athanasopoulos A. Haiderali M. Huang I. Gountas A. Skroumpelos A. Karokis